Coty Shareholder Class Action Reminder
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy COTY?
Source: PRnewswire
- Class Action Notice: Rosen Law Firm reminds investors who purchased Coty Inc. (NYSE:COTY) common stock between November 5, 2025, and February 4, 2026, that they must apply to be lead plaintiff by May 22, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the Coty class action will incur no out-of-pocket expenses, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages more affected investors to participate in the litigation.
- Lawsuit Background: The lawsuit alleges that Coty made false or misleading statements during the class period, concealing the true state of its slowing growth in the beauty market, which resulted in investor losses when the truth emerged, highlighting the company's vulnerability in a competitive beauty industry.
- Law Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling similar cases.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy COTY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on COTY
Wall Street analysts forecast COTY stock price to rise
12 Analyst Rating
1 Buy
9 Hold
2 Sell
Hold
Current: 2.090
Low
2.50
Averages
4.30
High
10.00
Current: 2.090
Low
2.50
Averages
4.30
High
10.00
About COTY
Coty Inc. is a beauty company with a portfolio of brands across fragrance, color cosmetics, and skin and body care. The Company has a diverse portfolio of brands, which includes both owned and licensed. Its brand portfolio is classified into two segments: Consumer beauty and Prestige. The consumer beauty brands include Adidas, Beckham, Bozzano, Bourjois, Bruno Banani, CoverGirl, Jovan, Mexx, LeGer by Lena Gercke, Monange, Nautica, Paixao, Rimmel, Risque, Sally Hansen, and Vera Wang. Its prestige brands include Burberry, Calvin Klein, Chloe, Davidoff, Escada, Gucci, Hugo Boss, Jil Sander, Kylie Cosmetics by Kylie Jenner, Lancaster, Marc Jacobs, Miu Miu, Orveda, and Tiffany & Co. Its mass beauty brands are primarily sold through hypermarkets, supermarkets, drug stores and pharmacies, mid-tier department stores, traditional food and drug retailers, and dedicated e-commerce retailers. It markets, sells and distributes its products in over 120 countries and territories.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Coty Shareholder Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Coty Inc. (NYSE:COTY) common stock between November 5, 2025, and February 4, 2026, that they must apply to be lead plaintiff by May 22, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the Coty class action will incur no out-of-pocket expenses, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages more affected investors to participate in the litigation.
- Lawsuit Background: The lawsuit alleges that Coty made false or misleading statements during the class period, concealing the true state of its slowing growth in the beauty market, which resulted in investor losses when the truth emerged, highlighting the company's vulnerability in a competitive beauty industry.
- Law Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling similar cases.
See More
Multiple Companies Face Class Action Lawsuits
- Atara Biotherapeutics Lawsuit: Atara is facing allegations for the period from May 20, 2024, to January 9, 2026, for failing to disclose manufacturing issues that jeopardized FDA approval for tabelecleucel, potentially leading to significant negative impacts on its financial condition.
- Coty Performance Issues: Coty Inc. is accused during the period from November 5, 2025, to February 4, 2026, of concealing underperformance in its Consumer Beauty segment and increased marketing investments that compressed margins, misleading investors about its business outlook.
- Super Micro Compliance Violations: Super Micro Computer is under scrutiny for the period from April 30, 2024, to March 19, 2026, for failing to disclose that a significant portion of its server sales to China violated U.S. export control laws, exposing the company to regulatory risks.
- ImmunityBio Capability Overstatement: ImmunityBio is facing allegations from January 19, 2026, to March 24, 2026, for overstating Anktiva's capabilities, resulting in misleading positive statements about the company's business prospects.
See More
Coty Class Action Lawsuit Reminder for Investors
- Class Action Notice: Rosen Law Firm reminds investors who purchased Coty Inc. (NYSE: COTY) common stock between November 5, 2025, and February 4, 2026, to apply as lead plaintiffs by May 22, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the Coty class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, significantly reducing the financial burden on investors.
- Lawsuit Background: The lawsuit alleges that Coty made false and/or misleading statements during the class period, concealing the true state of its slowing growth in the beauty market, which resulted in investor losses once the truth was revealed.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, highlighting its expertise and success in this field.
See More
Coty Faces Securities Class Action Lawsuit Amid Operational Issues
- Lawsuit Background: Coty Inc. is facing a securities class action lawsuit representing investors who purchased stock between November 5, 2025, and February 4, 2026, following a Q2 2026 earnings report that revealed serious operational issues, causing shares to drop over 8% on the announcement day.
- Executive Departure: The abrupt departure of CEO Nabi on December 12, 2025, without explanation, has raised concerns about internal management and future prospects, exacerbating investor anxiety and contributing to the stock's decline.
- Deteriorating Financial Performance: In the Q2 2026 report, Coty's Consumer Beauty segment reported a staggering over 70% drop in operating income year-over-year, while Prestige fragrance income fell over 18%, leading the company to withdraw its FY 2026 EBITDA and free cash flow guidance, indicating a significant deterioration in financial health.
- Investor Warning: Hagens Berman is investigating whether Coty intentionally misled investors regarding its business trends, urging those who suffered significant losses to submit their information to support potential claims, highlighting the seriousness of the situation.
See More
Class Action Lawsuits Filed for Multiple Companies
- Lufax Shareholder Lawsuit: Shareholders of Lufax Holding Ltd. have filed a class action lawsuit due to the company's failure to disclose inadequate internal controls and misstated financial results during the period from April 7, 2023, to January 26, 2025, with a lead plaintiff deadline of May 20, 2026.
- Atara Biotherapeutics Lawsuit: Shareholders of Atara Biotherapeutics, Inc. have initiated a lawsuit alleging that the company failed to disclose manufacturing issues and clinical trial risks from May 20, 2024, to January 9, 2026, potentially jeopardizing FDA approval, with a lead plaintiff deadline of May 22, 2026.
- Coty Shareholder Class Action: Coty Inc. shareholders have filed a class action lawsuit due to the company's failure to disclose underperformance in its Consumer Beauty segment and slowing market growth from November 5, 2025, to February 4, 2026, with a lead plaintiff deadline of May 22, 2026.
- Legal Consultation Reminder: The Law Offices of Frank R. Cruz remind investors who suffered losses during these periods to contact them for legal advice to protect their rights and interests.
See More
Coty Faces Class Action Lawsuit from Investors
- Class Action Filed: Bronstein, Gewirtz & Grossman LLC has initiated a class action lawsuit against Coty Inc., seeking damages for investors who purchased Coty securities between November 5, 2025, and February 4, 2026, reflecting significant investor dissatisfaction with the company's financial transparency.
- Allegations of False Statements: The complaint alleges that Coty made overly optimistic statements regarding its growth and profitability prospects for fiscal year 2026 while failing to disclose a slowdown in its Consumer Beauty segment and margin pressures from increased marketing expenditures, resulting in investor losses.
- Negative Market Reaction: The deceleration in Coty's Prestige fragrance segment has undermined investor confidence in the company's future, potentially leading to further declines in stock price and impacting its position in the highly competitive beauty market.
- No Cost to Investors: The law firm operates on a contingency fee basis, meaning investors will not incur any costs unless the lawsuit is successful, which may encourage more affected investors to join the class action.
See More
Coty Shareholder Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Coty Inc. (NYSE:COTY) common stock between November 5, 2025, and February 4, 2026, that they must apply to be lead plaintiff by May 22, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the Coty class action will incur no out-of-pocket expenses, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages more affected investors to participate in the litigation.
- Lawsuit Background: The lawsuit alleges that Coty made false or misleading statements during the class period, concealing the true state of its slowing growth in the beauty market, which resulted in investor losses when the truth emerged, highlighting the company's vulnerability in a competitive beauty industry.
- Law Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling similar cases.
See More
Multiple Companies Face Class Action Lawsuits
- Atara Biotherapeutics Lawsuit: Atara is facing allegations for the period from May 20, 2024, to January 9, 2026, for failing to disclose manufacturing issues that jeopardized FDA approval for tabelecleucel, potentially leading to significant negative impacts on its financial condition.
- Coty Performance Issues: Coty Inc. is accused during the period from November 5, 2025, to February 4, 2026, of concealing underperformance in its Consumer Beauty segment and increased marketing investments that compressed margins, misleading investors about its business outlook.
- Super Micro Compliance Violations: Super Micro Computer is under scrutiny for the period from April 30, 2024, to March 19, 2026, for failing to disclose that a significant portion of its server sales to China violated U.S. export control laws, exposing the company to regulatory risks.
- ImmunityBio Capability Overstatement: ImmunityBio is facing allegations from January 19, 2026, to March 24, 2026, for overstating Anktiva's capabilities, resulting in misleading positive statements about the company's business prospects.
See More
Coty Class Action Lawsuit Reminder for Investors
- Class Action Notice: Rosen Law Firm reminds investors who purchased Coty Inc. (NYSE: COTY) common stock between November 5, 2025, and February 4, 2026, to apply as lead plaintiffs by May 22, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the Coty class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, significantly reducing the financial burden on investors.
- Lawsuit Background: The lawsuit alleges that Coty made false and/or misleading statements during the class period, concealing the true state of its slowing growth in the beauty market, which resulted in investor losses once the truth was revealed.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, highlighting its expertise and success in this field.
See More
Coty Faces Securities Class Action Lawsuit Amid Operational Issues
- Lawsuit Background: Coty Inc. is facing a securities class action lawsuit representing investors who purchased stock between November 5, 2025, and February 4, 2026, following a Q2 2026 earnings report that revealed serious operational issues, causing shares to drop over 8% on the announcement day.
- Executive Departure: The abrupt departure of CEO Nabi on December 12, 2025, without explanation, has raised concerns about internal management and future prospects, exacerbating investor anxiety and contributing to the stock's decline.
- Deteriorating Financial Performance: In the Q2 2026 report, Coty's Consumer Beauty segment reported a staggering over 70% drop in operating income year-over-year, while Prestige fragrance income fell over 18%, leading the company to withdraw its FY 2026 EBITDA and free cash flow guidance, indicating a significant deterioration in financial health.
- Investor Warning: Hagens Berman is investigating whether Coty intentionally misled investors regarding its business trends, urging those who suffered significant losses to submit their information to support potential claims, highlighting the seriousness of the situation.
See More
Class Action Lawsuits Filed for Multiple Companies
- Lufax Shareholder Lawsuit: Shareholders of Lufax Holding Ltd. have filed a class action lawsuit due to the company's failure to disclose inadequate internal controls and misstated financial results during the period from April 7, 2023, to January 26, 2025, with a lead plaintiff deadline of May 20, 2026.
- Atara Biotherapeutics Lawsuit: Shareholders of Atara Biotherapeutics, Inc. have initiated a lawsuit alleging that the company failed to disclose manufacturing issues and clinical trial risks from May 20, 2024, to January 9, 2026, potentially jeopardizing FDA approval, with a lead plaintiff deadline of May 22, 2026.
- Coty Shareholder Class Action: Coty Inc. shareholders have filed a class action lawsuit due to the company's failure to disclose underperformance in its Consumer Beauty segment and slowing market growth from November 5, 2025, to February 4, 2026, with a lead plaintiff deadline of May 22, 2026.
- Legal Consultation Reminder: The Law Offices of Frank R. Cruz remind investors who suffered losses during these periods to contact them for legal advice to protect their rights and interests.
See More
Coty Faces Class Action Lawsuit from Investors
- Class Action Filed: Bronstein, Gewirtz & Grossman LLC has initiated a class action lawsuit against Coty Inc., seeking damages for investors who purchased Coty securities between November 5, 2025, and February 4, 2026, reflecting significant investor dissatisfaction with the company's financial transparency.
- Allegations of False Statements: The complaint alleges that Coty made overly optimistic statements regarding its growth and profitability prospects for fiscal year 2026 while failing to disclose a slowdown in its Consumer Beauty segment and margin pressures from increased marketing expenditures, resulting in investor losses.
- Negative Market Reaction: The deceleration in Coty's Prestige fragrance segment has undermined investor confidence in the company's future, potentially leading to further declines in stock price and impacting its position in the highly competitive beauty market.
- No Cost to Investors: The law firm operates on a contingency fee basis, meaning investors will not incur any costs unless the lawsuit is successful, which may encourage more affected investors to join the class action.
See More
